Karyopharm Therapeutics Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Newton, MA
KPTI chart
What traders are saying about $KPTI
Latest postsKaryopharm Therapeutics Inc. news
- Top 5 Healthcare Decliners Among Market Movers on November 10, 2026: Karyopharm Therapeutics (NASDAQ:KPTI) -34.75%, Exagen (NASDAQ:XGN) -25.99%, TriSalus Life Sciences (NASDAQ:TLSI) -23.76%, CDT Equity (NASDAQ:CDT) -23.52%, Curis (
kalkine.ca ·
- Top 5 More Losers Among the Market Movers on November 10, 2026: Zeta Network Group (NASDAQ:ZNB) -38.90%, Evolution Metals & Technologies (NASDAQ:EMAT) -37.84%, Digital Turbine (NASDAQ:APPS) -35.58%, Karyopharm Therapeutics (NASDAQ:
kalkine.ca ·
- Top 5 Healthcare Pre-Market Losers on Tuesday: Karyopharm Therapeutics (NASDAQ:KPTI) -22.25%, Jin Medical International (NASDAQ:ZJYL) -17.7%, Adagio Medical Holdings (NASDAQ:ADGM) -15.62%, Lakewood-Amedex (NASDAQ:LABT) -11%, Blueja
Kalkine ·
- Top 5 Pre-Market Names in Chapter 11, Reverse Splits and Restructuring: Karyopharm Therapeutics (NASDAQ:KPTI) -22.25%, The Children's Place (NASDAQ:PLCE) -9.24%, Republic Power Group (NASDAQ:RPGL) +14.25%, Liminatus Pharma (NASDAQ:LI
Kalkine ·
- Top 5 Pre-Market Decliners Priced Below USD 1.00 on Tuesday: Microvast Holdings (NASDAQ:MVST) -49.17%, Karyopharm Therapeutics (NASDAQ:KPTI) -22.25%, Vivakor (NASDAQ:VIVK) -19.4%, Flux Power (NASDAQ:FLUX) -15.9%, Parabolic Technologi
Kalkine ·
- 12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga ·
- Case Summary: Karyopharm Therapeutics Chapter 11
Bondoro ·
- Weekly Recap: Chapter 11 sale plan and Rodman & Renshaw downgrade
TradingView ·
- Karyopharm Therapeutics Inc (25K0.DU) Seasonal returns chart
Yahoo Finance Australia ·
- Karyopharm Therapeutics Inc. (25K0.F) Analyst insights, Price targets and Recommendations
Yahoo Finance UK ·
- Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates
Kalkine ·
- 12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga ·
Karyopharm Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M |
| Net income | -$196.0M | -$76.4M | -$143.1M | -$165.3M |
| Diluted EPS | $-17.93 | $-14.00 | $-18.79 | $-2.02 |
| Total assets (year end) | $108.4M | $164.4M | $240.4M | $358.2M |
| Cash and equivalents (year end) | $60.5M | $62.5M | $52.2M | $135.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Karyopharm Therapeutics Inc.
- Ticker
- KPTI (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Newton, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1503802
Frequently asked questions
What exchange is Karyopharm Therapeutics Inc. listed on?
Karyopharm Therapeutics Inc. trades on the Nasdaq under the ticker symbol KPTI.
What industry is Karyopharm Therapeutics Inc. in?
Karyopharm Therapeutics Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Karyopharm Therapeutics Inc. headquartered?
Karyopharm Therapeutics Inc.'s business address on file with the SEC is in Newton, MA.
When does Karyopharm Therapeutics Inc.'s fiscal year end?
Karyopharm Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Karyopharm Therapeutics Inc. report?
Karyopharm Therapeutics Inc. reported $146.1M in revenue for calendar year 2025, according to its SEC filings.